Industry: Medical Devices & Consumables
Published Date: 2025-03-10
Pages: 128 Pages
Report ld: 4618769
Request Sample
Customized Report
Human Recombinant LIF Market Size(US$)

CAGR 2025-2031
6.5%
Market Size,2031
USD 565
Million
Market Snapshot
Source: Secondary research, interviews with experts, and QYResearch analysis
The global market for Human Recombinant LIF was estimated to be worth US$ 366 million in 2024 and is forecast to a readjusted size of US$ 565 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.
Leukemia inhibitory factor (LIF) is a pleiotropic factor produced by multiple cell types, including T cells, myelomonocytic lineage, fibroblasts, liver, heart, and melanoma. LIF promotes the long-term maintenance of embryonic stem cells by inhibiting spontaneous differentiation.
North American market for Human Recombinant LIF was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Human Recombinant LIF was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Human Recombinant LIF was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global key companies of Human Recombinant LIF include STEMCELL, Merck, YEASEN, Dalian Meilun Biotech Co., Ltd., R&D Systems, Inc., Thermo Fisher Scientific Inc., Cell Guidance Systems LLC, Prospec-Tany Technogene Ltd., ACROBiosystems, Neuromics, etc. In 2024, the global five largest players hold a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Human Recombinant LIF, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Human Recombinant LIF by region & country, by Type, and by Application.
The Human Recombinant LIF market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Recombinant LIF.
MARKET SEGMENTATION
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Human Recombinant LIF manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Human Recombinant LIF in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Human Recombinant LIF in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
We identify regional market threats and growth prospects to guide your overseas layout.
We adjust product portfolios in line with local consumption habits.
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Market Overview
1.1 Human Recombinant LIF Product Introduction
1.2 Global Human Recombinant LIF Market Size Forecast
1.2.1 Global Human Recombinant LIF Sales Value (2020-2031)
1.2.2 Global Human Recombinant LIF Sales Volume (2020-2031)
1.2.3 Global Human Recombinant LIF Sales Price (2020-2031)
1.3 Human Recombinant LIF Market Trends & Drivers
1.3.1 Human Recombinant LIF Industry Trends
1.3.2 Human Recombinant LIF Market Drivers & Opportunity
1.3.3 Human Recombinant LIF Market Challenges
1.3.4 Human Recombinant LIF Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Human Recombinant LIF Players Revenue Ranking (2024)
2.2 Global Human Recombinant LIF Revenue by Company (2020-2025)
2.3 Global Human Recombinant LIF Players Sales Volume Ranking (2024)
2.4 Global Human Recombinant LIF Sales Volume by Company Players (2020-2025)
2.5 Global Human Recombinant LIF Average Price by Company (2020-2025)
2.6 Key Manufacturers Human Recombinant LIF Manufacturing Base and Headquarters
2.7 Key Manufacturers Human Recombinant LIF Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Human Recombinant LIF
2.9 Human Recombinant LIF Market Competitive Analysis
2.9.1 Human Recombinant LIF Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Human Recombinant LIF Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Recombinant LIF as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Purity < 97%
3.1.2 Purity ≥ 97%
3.2 Global Human Recombinant LIF Sales Value by Type
3.2.1 Global Human Recombinant LIF Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Human Recombinant LIF Sales Value, by Type (2020-2031)
3.2.3 Global Human Recombinant LIF Sales Value, by Type (%) (2020-2031)
3.3 Global Human Recombinant LIF Sales Volume by Type
3.3.1 Global Human Recombinant LIF Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Human Recombinant LIF Sales Volume, by Type (2020-2031)
3.3.3 Global Human Recombinant LIF Sales Volume, by Type (%) (2020-2031)
3.4 Global Human Recombinant LIF Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Laboratory
4.1.2 University
4.1.3 Others
4.2 Global Human Recombinant LIF Sales Value by Application
4.2.1 Global Human Recombinant LIF Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Human Recombinant LIF Sales Value, by Application (2020-2031)
4.2.3 Global Human Recombinant LIF Sales Value, by Application (%) (2020-2031)
4.3 Global Human Recombinant LIF Sales Volume by Application
4.3.1 Global Human Recombinant LIF Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Human Recombinant LIF Sales Volume, by Application (2020-2031)
4.3.3 Global Human Recombinant LIF Sales Volume, by Application (%) (2020-2031)
4.4 Global Human Recombinant LIF Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Human Recombinant LIF Sales Value by Region
5.1.1 Global Human Recombinant LIF Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Human Recombinant LIF Sales Value by Region (2020-2025)
5.1.3 Global Human Recombinant LIF Sales Value by Region (2026-2031)
5.1.4 Global Human Recombinant LIF Sales Value by Region (%), (2020-2031)
5.2 Global Human Recombinant LIF Sales Volume by Region
5.2.1 Global Human Recombinant LIF Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Human Recombinant LIF Sales Volume by Region (2020-2025)
5.2.3 Global Human Recombinant LIF Sales Volume by Region (2026-2031)
5.2.4 Global Human Recombinant LIF Sales Volume by Region (%), (2020-2031)
5.3 Global Human Recombinant LIF Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Human Recombinant LIF Sales Value, 2020-2031
5.4.2 North America Human Recombinant LIF Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Human Recombinant LIF Sales Value, 2020-2031
5.5.2 Europe Human Recombinant LIF Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Human Recombinant LIF Sales Value, 2020-2031
5.6.2 Asia Pacific Human Recombinant LIF Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Human Recombinant LIF Sales Value, 2020-2031
5.7.2 South America Human Recombinant LIF Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Human Recombinant LIF Sales Value, 2020-2031
5.8.2 Middle East & Africa Human Recombinant LIF Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Human Recombinant LIF Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Human Recombinant LIF Sales Value and Sales Volume
6.2.1 Key Countries/Regions Human Recombinant LIF Sales Value, 2020-2031
6.2.2 Key Countries/Regions Human Recombinant LIF Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Human Recombinant LIF Sales Value, 2020-2031
6.3.2 United States Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Human Recombinant LIF Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Human Recombinant LIF Sales Value, 2020-2031
6.4.2 Europe Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Human Recombinant LIF Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Human Recombinant LIF Sales Value, 2020-2031
6.5.2 China Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031
6.5.3 China Human Recombinant LIF Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Human Recombinant LIF Sales Value, 2020-2031
6.6.2 Japan Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Human Recombinant LIF Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Human Recombinant LIF Sales Value, 2020-2031
6.7.2 South Korea Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Human Recombinant LIF Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Human Recombinant LIF Sales Value, 2020-2031
6.8.2 Southeast Asia Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Human Recombinant LIF Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Human Recombinant LIF Sales Value, 2020-2031
6.9.2 India Human Recombinant LIF Sales Value by Type (%), 2024 VS 2031
6.9.3 India Human Recombinant LIF Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 STEMCELL
7.1.1 STEMCELL Company Information
7.1.2 STEMCELL Introduction and Business Overview
7.1.3 STEMCELL Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 STEMCELL Human Recombinant LIF Product Offerings
7.1.5 STEMCELL Recent Development
7.2 Merck
7.2.1 Merck Company Information
7.2.2 Merck Introduction and Business Overview
7.2.3 Merck Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Merck Human Recombinant LIF Product Offerings
7.2.5 Merck Recent Development
7.3 YEASEN
7.3.1 YEASEN Company Information
7.3.2 YEASEN Introduction and Business Overview
7.3.3 YEASEN Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 YEASEN Human Recombinant LIF Product Offerings
7.3.5 YEASEN Recent Development
7.4 Dalian Meilun Biotech Co., Ltd.
7.4.1 Dalian Meilun Biotech Co., Ltd. Company Information
7.4.2 Dalian Meilun Biotech Co., Ltd. Introduction and Business Overview
7.4.3 Dalian Meilun Biotech Co., Ltd. Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Dalian Meilun Biotech Co., Ltd. Human Recombinant LIF Product Offerings
7.4.5 Dalian Meilun Biotech Co., Ltd. Recent Development
7.5 R&D Systems, Inc.
7.5.1 R&D Systems, Inc. Company Information
7.5.2 R&D Systems, Inc. Introduction and Business Overview
7.5.3 R&D Systems, Inc. Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 R&D Systems, Inc. Human Recombinant LIF Product Offerings
7.5.5 R&D Systems, Inc. Recent Development
7.6 Thermo Fisher Scientific Inc.
7.6.1 Thermo Fisher Scientific Inc. Company Information
7.6.2 Thermo Fisher Scientific Inc. Introduction and Business Overview
7.6.3 Thermo Fisher Scientific Inc. Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Thermo Fisher Scientific Inc. Human Recombinant LIF Product Offerings
7.6.5 Thermo Fisher Scientific Inc. Recent Development
7.7 Cell Guidance Systems LLC
7.7.1 Cell Guidance Systems LLC Company Information
7.7.2 Cell Guidance Systems LLC Introduction and Business Overview
7.7.3 Cell Guidance Systems LLC Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Cell Guidance Systems LLC Human Recombinant LIF Product Offerings
7.7.5 Cell Guidance Systems LLC Recent Development
7.8 Prospec-Tany Technogene Ltd.
7.8.1 Prospec-Tany Technogene Ltd. Company Information
7.8.2 Prospec-Tany Technogene Ltd. Introduction and Business Overview
7.8.3 Prospec-Tany Technogene Ltd. Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Prospec-Tany Technogene Ltd. Human Recombinant LIF Product Offerings
7.8.5 Prospec-Tany Technogene Ltd. Recent Development
7.9 ACROBiosystems
7.9.1 ACROBiosystems Company Information
7.9.2 ACROBiosystems Introduction and Business Overview
7.9.3 ACROBiosystems Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 ACROBiosystems Human Recombinant LIF Product Offerings
7.9.5 ACROBiosystems Recent Development
7.10 Neuromics
7.10.1 Neuromics Company Information
7.10.2 Neuromics Introduction and Business Overview
7.10.3 Neuromics Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Neuromics Human Recombinant LIF Product Offerings
7.10.5 Neuromics Recent Development
7.11 BioLegend, Inc
7.11.1 BioLegend, Inc Company Information
7.11.2 BioLegend, Inc Introduction and Business Overview
7.11.3 BioLegend, Inc Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 BioLegend, Inc Human Recombinant LIF Product Offerings
7.11.5 BioLegend, Inc Recent Development
7.12 InVitria
7.12.1 InVitria Company Information
7.12.2 InVitria Introduction and Business Overview
7.12.3 InVitria Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 InVitria Human Recombinant LIF Product Offerings
7.12.5 InVitria Recent Development
7.13 BPS Bioscience
7.13.1 BPS Bioscience Company Information
7.13.2 BPS Bioscience Introduction and Business Overview
7.13.3 BPS Bioscience Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)
7.13.4 BPS Bioscience Human Recombinant LIF Product Offerings
7.13.5 BPS Bioscience Recent Development
7.14 ScienCell Research Laboratories, Inc
7.14.1 ScienCell Research Laboratories, Inc Company Information
7.14.2 ScienCell Research Laboratories, Inc Introduction and Business Overview
7.14.3 ScienCell Research Laboratories, Inc Human Recombinant LIF Sales, Revenue, Price and Gross Margin (2020-2025)
7.14.4 ScienCell Research Laboratories, Inc Human Recombinant LIF Product Offerings
7.14.5 ScienCell Research Laboratories, Inc Recent Development
8 Industry Chain Analysis
8.1 Human Recombinant LIF Industrial Chain
8.2 Human Recombinant LIF Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Human Recombinant LIF Sales Model
8.5.2 Sales Channel
8.5.3 Human Recombinant LIF Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
List of Figures
KEY QUESTIONS ADDRESSED BY THE REPORT
Related Reports
The global Human Recombinant LIF market is projected to grow from US$ 387 million in 2025 to US$ 598 million by 2032, at a CAGR of 6.5% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-03-26
Pages: 158
USD 4900.00
(Single User License)
The global Human Recombinant LIF market size was US$ 387 million in 2025 and is forecast to reach a readjusted size of US$ 598 million by 2032 with a CAGR of 6.5% during the forecast period 2026-2032.
Published Date: 2026-03-26
Pages: 97
USD 4250.00
(Single User License)
The global market for Human Recombinant LIF was estimated to be worth US$ 387 million in 2025 and is projected to reach US$ 598 million, growing at a CAGR of 6.5% from 2026 to 2032.
Published Date: 2026-01-08
Pages: 124
USD 3950.00
(Single User License)
The global Human Recombinant LIF market was valued at US$ 387 million in 2025 and is anticipated to reach US$ 598 million by 2032, at a CAGR of 6.5% from 2026 to 2032.
Published Date: 2026-01-08
Pages: 120
USD 2900.00
(Single User License)
The global Human Recombinant LIF market is projected to grow from US$ 366 million in 2024 to US$ 565 million by 2031, at a CAGR of 6.5% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-08-05
Pages: 162
USD 4900.00
(Single User License)
The global Human Recombinant LIF market size was US$ 366 million in 2024 and is forecast to a readjusted size of US$ 565 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.
Published Date: 2025-08-01
Pages: 95
USD 4250.00
(Single User License)
The global market for Human Recombinant LIF was valued at US$ 366 million in the year 2024 and is projected to reach a revised size of US$ 565 million by 2031, growing at a CAGR of 6.5% during the forecast period.
Published Date: 2025-03-10
Pages: 93
USD 2900.00
(Single User License)
The global Human Recombinant LIF market is projected to grow from US$ 366 million in 2024 to US$ 534 million by 2030, at a Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period.
Published Date: 2024-11-12
Pages: 155
USD 4900.00
(Single User License)
The global Human Recombinant LIF revenue was US$ 341 million in 2023 and is forecast to a readjusted size of US$ 534 million by 2030 with a CAGR of 6.5% during the review period (2024-2030).
Published Date: 2024-11-12
Pages: 123
USD 4350.00
(Single User License)
The global market for Human Recombinant LIF was estimated to be worth US$ 341 million in 2023 and is forecast to a readjusted size of US$ 534 million by 2030 with a CAGR of 6.5% during the forecast period 2024-2030.
Published Date: 2024-11-12
Pages: 113
USD 3950.00
(Single User License)
The global Human Recombinant LIF market is projected to grow from US$ 387 million in 2025 to US$ 598 million by 2032, at a CAGR of 6.5% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-03-26
Pages: 158
The global Human Recombinant LIF market size was US$ 387 million in 2025 and is forecast to reach a readjusted size of US$ 598 million by 2032 with a CAGR of 6.5% during the forecast period 2026-2032.
Published: 2026-03-26
Pages: 97
The global market for Human Recombinant LIF was estimated to be worth US$ 387 million in 2025 and is projected to reach US$ 598 million, growing at a CAGR of 6.5% from 2026 to 2032.
Published: 2026-01-08
Pages: 124
The global Human Recombinant LIF market was valued at US$ 387 million in 2025 and is anticipated to reach US$ 598 million by 2032, at a CAGR of 6.5% from 2026 to 2032.
Published: 2026-01-08
Pages: 120
The global Human Recombinant LIF market is projected to grow from US$ 366 million in 2024 to US$ 565 million by 2031, at a CAGR of 6.5% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-08-05
Pages: 162
The global Human Recombinant LIF market size was US$ 366 million in 2024 and is forecast to a readjusted size of US$ 565 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.
Published: 2025-08-01
Pages: 95
The global market for Human Recombinant LIF was valued at US$ 366 million in the year 2024 and is projected to reach a revised size of US$ 565 million by 2031, growing at a CAGR of 6.5% during the forecast period.
Published: 2025-03-10
Pages: 93
The global Human Recombinant LIF market is projected to grow from US$ 366 million in 2024 to US$ 534 million by 2030, at a Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period.
Published: 2024-11-12
Pages: 155
The global Human Recombinant LIF revenue was US$ 341 million in 2023 and is forecast to a readjusted size of US$ 534 million by 2030 with a CAGR of 6.5% during the review period (2024-2030).
Published: 2024-11-12
Pages: 123
The global market for Human Recombinant LIF was estimated to be worth US$ 341 million in 2023 and is forecast to a readjusted size of US$ 534 million by 2030 with a CAGR of 6.5% during the forecast period 2024-2030.
Published: 2024-11-12
Pages: 113
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now